Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery offers hope for extended survival in patients with regionally advanced non-small cell lung cancer (NSCLC), particularly those patients with ipsilateral mediastinal nodal involvement. However, neoadjuvant therapies are sometimes associated with pulmonary toxicity. A recent large scale analysis using the Society of Thoracic Surgery (STS) General Thoracic Surgery Database identified induction therapy as an independent predictor of postoperative pulmonary complications.1 The present chapter reviews the effects of neoadjuvant therapy on pulmonary function as well as perioperative morbidity and mortality, and examines whether altering the timing of resection can reduce the risk of complications.
|Original language||English (US)|
|Title of host publication||Difficult Decisions in Thoracic Surgery (Second Edition)|
|Subtitle of host publication||An Evidence-Based Approach|
|Number of pages||6|
|State||Published - Dec 1 2011|